Hit enter to search or ESC to close
All News on IPO
IPO Details Price:$1 , on 10 June 2025 and distribution yield > 7% Purpose of IPO RM 560 M raised solely via offer-for-sale by WCT Holdings—parcels of existing units; no new proceeds flow to Paradigm REIT itself...
IPO Details Listing date: 9 June 2025 at RM 0.16 IPO price, Target price: RM 0.20 IPO oversubscribed by 5.33× (196.2 M units applied for 31 M offered). Bumiputera public: 2.94×, Other Malaysian public: 7.72×. Purpose of...
IPO Details Purpose of IPO: Signature Alliance Group Berhad (SAG) is raising RM161.2 million with the following allocation: RM88.0 million (54.6%) for acquisition of land and building a new HQ/facility. RM30.1 million (18.7%) for...
ICT Zone Asia Berhad IPO Evaluation IPO Details Purpose of IPOICT Zone Asia Berhad aims to raise RM26.6 million through the issuance of 133 million new shares at RM0.20 each. The funds will be...
📢 Shouhui Group (02621.HK) IPO: A Deep Dive into the Upcoming Listing 📌 IPO Snapshot Offer Price Range: HK$6.48 to HK$8.08 per share Board Lot Size: 400 shares Entry Fee: Approximately HK$3,264.59 Total Shares...
Oasis Home IPO: First-Mover in Malaysia’s Live Commerce Revolution—Here’s What You Need to Know IPO Details Purpose of IPO The company aims to raise RM28 million through the issuance of 100 million new shares...
Healthcare S-REITs have emerged as the top-performing sub-sector in 2025, delivering an average total return of 6.2% year-to-date—significantly outperforming the broader iEdge S-REIT Index, which fell 1.1%. Over one- and three-year periods, the...
At least five companies from mainland China and Hong Kong are exploring IPOs, dual listings, or share placements on the Singapore Exchange (SGX) over the next 12 to 18 months, according to four sources...
1. IPO Details Purpose of IPO: Mirxes aims to raise approximately HKD 1.086 billion (USD 139 million) through its IPO. The proceeds are intended to support the commercialization of its gastric cancer test, further...
IPO Details Purpose of IPO: Hengrui Pharma aims to raise up to HK$9.89 billion (US$1.27 billion) through its Hong Kong listing. The proceeds are allocated as follows: Approximately 45% for funding clinical studies of...
